Aurora Cannabis and Vectura Fertin Pharma Inc. Announce Commercial Collaboration

Collaboration to leverage industry-leading expertise and capabilities

Aurora Cannabis and Vectura Fertin Pharma Inc. are pleased to announce that they have entered into a commercial collaboration.

This collaboration will see the launch of a new CBD lozenge from Cogent International, a Vectura Fertin subsidiary. The lozenge will be manufactured by Aurora and will be marketed and distributed by Vectura Fertin. This is an exciting development for both companies, and we believe that it will be a successful partnership.

Aurora Cannabis is a leading Canadian-based global medical cannabis company. The company has a portfolio of high-quality, innovative cannabis products that are sold in a variety of markets around the world. Aurora is committed to providing patients with safe, effective and affordable medical cannabis.

Vectura Fertin Pharma Inc. is a leading provider of inhaled and nasal drug delivery systems. The company has a proven track record of developing and commercializing innovative products that meet the needs of patients. Vectura Fertin is committed to providing patients with high-quality, effective, and affordable inhaled and nasal drug delivery systems.

We believe that this collaboration will be a success because it combines the strengths of two leading companies in the cannabis and pharmaceutical industries. Aurora has the experience and expertise in cannabis cultivation and production, while Vectura Fertin has the expertise in drug delivery systems. Together, we believe that we can create a product that will meet the needs of patients and improve their lives.